Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer, April 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 202 articles: HTML format

Single Articles

1. SPEZIALE R, Iacovelli V, Leoni G, Anzillotti L, et al
   Plasma metabolomic profiling identifies a metabolic signature for non-muscle-invasive bladder cancer independent of hematuria.
   Biol Direct. 2026 Apr 3. doi: 10.1186/s13062-026-00766.
   PubMed    
   Abstract available
   
   

2. GRUBA N, Stachurski L, Lesner A
   Utility of FRET substrates in bladder cancer diagnosis.
   Bioorg Chem. 2026;175:109818.
   PubMed    
   Abstract available
   
   

3. SUN S, Zhang J, Zheng Z, Hao Y, et al
   PSMD2-Mediated MAPK Signaling Promotes Bladder Cancer Development and Immune Microenvironment Remodeling.
   Oncol Res. 2026;34:30.
   PubMed    
   Abstract available
   
   

4. GIORGIONE R, Grasso D, Gambale E, Scolari F, et al
   Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.
   Oncol Res. 2026;34:1.
   PubMed    
   Abstract available
   
   

5. SHIBAMORI K, Hashimoto K, Okabe K, Maehana T, et al
   Absence of bladder cancer cells in surgical smoke from robot-assisted radical cystectomy: a prospective study.
   Front Urol. 2026;6:1714844.
   PubMed    
   Abstract available
   
   

6. MAGNANI CJ, D'Andrea VD, Barros GG, Qian Z, et al
   Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.
   medRxiv [Preprint]. 2026 Mar 24:2025.01.10.25320337.
   PubMed    
   Abstract available
   
   

7. ZHOU L, Chen Y, Yuan X, Guo F, et al
   Experiential Aspects in Patients With Permanent Urostomy Following Bladder Cancer Surgery: Meta-Synthesis of Qualitative Studies.
   Nurs Open. 2026;13:e70517.
   PubMed    
   Abstract available
   
   

8. HUA X, Huang M, Deng X, Xu J, et al
   Correction: The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein.
   Cell Death Differ. 2026 Apr 2. doi: 10.1038/s41418-026-01721.
   PubMed    
   
   
   

9. GUO X, Wang S, Ma Y, Chen Y, et al
   Efficacy and safety of RC48 alone or combined with PD-1 inhibitors in high-risk non-muscle invasive bladder cancer.
   Sci Rep. 2026 Apr 2. doi: 10.1038/s41598-026-43393.
   PubMed    
   
   
   

10. YAN YC, Guo Q, Xu J, Wei Z, et al
    Marked Non-Infectious Elevation of Procalcitonin in a Hemodialysis Patient with Bladder Cancer: A Case Report.
    Infect Drug Resist. 2026;19:569356.
    PubMed    
    Abstract available
    
    

11. CAO Y, Li C, Hua Y, Wu T, et al
    Multi-omics identification of a programmed cell death-related signature and potential target P4HB for bladder cancer based on a 101-combination machine learning and experimental validation.
    Clin Exp Med. 2026;26:214.
    PubMed    
    
    
    

12. GOKHALE P, Zapata LV
    Immune-Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis.
    Cancer Med. 2026;15:e71777.
    PubMed    
    Abstract available
    
    

13. KNEZEVIC M, Tomaskovic I, Murgic J, Vrhovec B, et al
    Immune landscape of muscle-invasive bladder cancer: role of TIGIT, LAG-3, and PD-L1.
    Front Immunol. 2026;17:1777409.
    PubMed    
    Abstract available
    
    

14. FRASCOLLA C, Mastroianni R, Macedo-Silva C, De Menna M, et al
    Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening.
    J Exp Clin Cancer Res. 2026 Apr 1. doi: 10.1186/s13046-026-03701.
    PubMed    
    
    
    

15. KAMAL AHM, Putluri V, Gandhi T, Ambati CSR, et al
    Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer.
    Cancer Metab. 2026;14:8.
    PubMed    
    Abstract available
    
    

16. KABUS M, Aumiller M, Ruhm A, Pongratz T, et al
    Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells.
    Sci Rep. 2026;16:11228.
    PubMed    
    Abstract available
    
    

17. DURRANI FA, Cacaccio J, Potter W, Dukh M, et al
    Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer.
    Mol Pharm. 2026 Apr 1. doi: 10.1021/acs.molpharmaceut.5c01678.
    PubMed    
    Abstract available
    
    

18. LIU R, Wang J
    Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.
    Front Oncol. 2026;16:1786965.
    PubMed    
    Abstract available
    
    

19. YI X, Zhao Z, Li J
    Development and validation of a risk prediction model for chemical cystitis in patients with non-muscle-invasive bladder cancer undergoing intravesical instillation.
    Oncol Rev. 2026;20:1791893.
    PubMed    
    Abstract available
    
    

20. KUSUMOTO H, Inoue M, Shishikura D, Kanzaki Y, et al
    Myocardial infarction due to nonbacterial thrombotic endocarditis in a patient with advanced bladder cancer.
    Cardiovasc Interv Ther. 2026 Mar 31. doi: 10.1007/s12928-026-01256.
    PubMed    
    
    
    

21. LIU X, Chen L, Lin L, Xie Y, et al
    PLZ4@SeD-induced ferroptosis sensitizes bladder cancer to chemotherapy and immunotherapy.
    Biomater Adv. 2026;185:214842.
    PubMed    
    Abstract available
    
    

22. YUAN Y, Xie T, Hu X, Wei X, et al
    Aptamer-Based Discovery of Neuropilin-2 as a Potential Biomarker and Therapeutic Target in Bladder Cancer.
    Anal Chem. 2026 Mar 31. doi: 10.1021/acs.analchem.5c07494.
    PubMed    
    Abstract available
    
    

23. BORRELLI A, Novelli S, Messina E, Laschena L, et al
    AI-assessed sarcopenia as an independent predictor of neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer.
    Radiol Med. 2026 Mar 31. doi: 10.1007/s11547-026-02203.
    PubMed    
    Abstract available
    
    

24. PRADO S, Ugge H, Vikerfors A, Fall K, et al
    Anti-Inflammatory Diet Index (AIDI) and Bladder Cancer Risk by Stage: A 22-Year Prospective Swedish Cohort Study (1998-2020).
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed    
    Abstract available
    
    

25. HE Y, Gong Y, Wu Y, He S, et al
    RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2.
    J Exp Clin Cancer Res. 2026 Mar 30. doi: 10.1186/s13046-026-03684.
    PubMed    
    
    
    

26. YI L, Chen Q, Zeng M, Xiao Z, et al
    Elevated intravesical pressure promotes circulating tumor cell release in an orthotopic mouse model of bladder cancer.
    In Vitro Cell Dev Biol Anim. 2026 Mar 30. doi: 10.1007/s11626-026-01176.
    PubMed    
    Abstract available
    
    

27. SU ZT, Florissi IS, Geller AE, Johnson Iii BA, et al
    Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment.
    J Natl Compr Canc Netw. 2026 Mar 19:1-7. doi: 10.6004/jnccn.2025.7129.
    PubMed    
    Abstract available
    
    

28. OTANI Y, Otani K, Rodden D, Lemieux M, et al
    PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality Therapy.
    J Natl Compr Canc Netw. 2026;24.
    PubMed    
    
    
    

29. CHI Q, Xu H, Li H, Ma G, et al
    Cx43 modulates malignant phenotypes in bladder cancer cells via the c-Src/PTEN/FAK axis.
    J Mol Histol. 2026;57:129.
    PubMed    
    Abstract available
    
    

30. CHEN D, Zhou Z, Wei G, Zhang F, et al
    Perioperative and oncological outcomes of thulium laser-ERBT versus conventional TURBT in non-muscle invasive bladder cancer: a meta-analysis of 2,934 patients.
    Lasers Med Sci. 2026;41:63.
    PubMed    
    Abstract available
    
    

31. JHA T, Ahuja A, Sharma M, Goel HK, et al
    Uncommon but aggressive: A case series on urinary bladder neuroendocrine carcinomas.
    J Cancer Res Ther. 2026;22:196-199.
    PubMed    
    Abstract available
    
    

32. AVILA-NIETO C, Jung G, Salih HR, Hagelstein I, et al
    Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.
    Front Immunol. 2026;17:1794705.
    PubMed    
    Abstract available
    
    

33. OLUWATOLA O, Bazargan S, Irrera P, Chang D, et al
    Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer.
    Front Immunol. 2026;17:1706250.
    PubMed    
    Abstract available
    
    

34. ZHUANG J, Wang H, Chen Z, Wang J, et al
    Baicalin chemosensitivity enhancement of cisplatin in bladder cancer via autophagy flux inhibition.
    Front Pharmacol. 2026;17:1676788.
    PubMed    
    Abstract available
    
    

35. WANG Q, Wang H, Lan P, Yang B, et al
    Integrative Transcriptomics, Machine Learning, and Molecular Dynamics Reveal Honghua Longdan (Gentiana rhodantha)?Modulated Therapeutic Targets in Bladder Cancer.
    ACS Omega. 2026;11:17996-18009.
    PubMed    
    Abstract available
    
    

36. RUSSO F, Tripodi L, Caldora F, Pandolfo SD, et al
    Identification of a weighted urinary microbial signature for bladder cancer discrimination.
    Front Oncol. 2026;16:1784501.
    PubMed    
    Abstract available
    
    

37. URSO L, Feletti F, Lancia F, Canella F, et al
    Diagnostic accuracy of (18)F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study.
    Front Med (Lausanne). 2026;13:1792243.
    PubMed    
    Abstract available
    
    

38. HEMMATI GHAVSHOUGH M, Fu MZ, Islam R, Patel D, et al
    Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across Risk Groups.
    Res Rep Urol. 2026;18:584499.
    PubMed    
    Abstract available
    
    

39. SATO T, Hayata N, Hida T, Miura T, et al
    [A Case of Asymptomatic Paraganglioma of the Bladder].
    Hinyokika Kiyo. 2026;72:1-6.
    PubMed    
    Abstract available
    
    

40. OU J, Ni K, Song H, Li G, et al
    The hidden burden: Clinical impact of incidental prostate cancer in bladder cancer patients.
    Chin Med J (Engl). 2026 Mar 30. doi: 10.1097/CM9.0000000000004031.
    PubMed    
    
    
    

41. BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
    Corrigendum to "Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies" [Gene 970 (2025) 149772].
    Gene. 2026 Mar 28:150129. doi: 10.1016/j.gene.2026.150129.
    PubMed    
    
    
    

42. PATEL KN, Yalla P, Panchal H, Pandya SJ, et al
    Is complete TURBT mandatory before radical cystectomy in cases of muscle-invasive bladder cancer?
    Urol Oncol. 2026 Mar 28:111080. doi: 10.1016/j.urolonc.2026.111080.
    PubMed    
    Abstract available
    
    

43. RIVES H, Fredette J, Anari F, Ghatalia P, et al
    Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer.
    Clin Genitourin Cancer. 2026 Mar 3:102525. doi: 10.1016/j.clgc.2026.102525.
    PubMed    
    Abstract available
    
    

44. UGRINOVSKI D, Saidi S, Stankov V, Ambardjieva M, et al
    Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer.
    Cancers (Basel). 2026;18:1026.
    PubMed    
    Abstract available
    
    

45. KIM DK, Jeon J, Kwon JK, Bang S, et al
    Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette-Guerin for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Cancers (Basel). 2026;18:990.
    PubMed    
    Abstract available
    
    

46. NTOUMAS GN, Kougioumtzopoulou A, Desse D, Fragkoulis C, et al
    Bladder Preservation with Concurrent Chemoradiotherapy Following Complete Response to Induction Systemic Therapy in Patients with Muscle-Invasive Bladder Cancer: A Review of the Existing Literature.
    Cancers (Basel). 2026;18:961.
    PubMed    
    Abstract available
    
    

47. LILLESAND M, Austdal M, Mroz J, Skaland I, et al
    Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:938.
    PubMed    
    Abstract available
    
    

48. SINGH SP, Liu R, Yan F, Tang Q, et al
    Galactokinase 1 Inhibition-Induced Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells Is Associated with AKT Signaling Downregulation.
    Int J Mol Sci. 2026;27:2911.
    PubMed    
    Abstract available
    
    

49. BAI J, Yu H, Hu C, Ma Y, et al
    Integrating Multi-Omics Atlas to Uncover Genetic and Epigenetic Mechanisms and Reveal Cell State Evolution Across Ecotypes in Male Urological Cancers.
    Int J Mol Sci. 2026;27:2712.
    PubMed    
    Abstract available
    
    

50. OLAH C, Juhasz D, Varadi M, Reis H, et al
    Molecular subtype concordance and metastatic patterns in muscle-invasive bladder cancer.
    J Pathol Clin Res. 2026;12:e70088.
    PubMed    
    Abstract available
    
    

51. LIU Y, Zhao T, Shi R, Xie Y, et al
    Cancer-associated fibroblasts in bladder cancer: Immunosuppressive mechanisms and therapeutic targeting.
    Semin Oncol. 2026;53:152483.
    PubMed    
    Abstract available
    
    

52. XIAO W, Zhang Z, Wang Y, Zhang W, et al
    Enhancing the performance of BP-MRI VI-RADS in detecting muscle-invasive bladder cancer: the potential role of supplementary quantitative parameters.
    Jpn J Radiol. 2026 Mar 27. doi: 10.1007/s11604-026-01970.
    PubMed    
    Abstract available
    
    

53. MARWAHA A, Sambhi R, Fernandes R
    Dermatomyositis as a Paraneoplastic Syndrome of Metastatic Urothelial Carcinoma.
    Curr Oncol. 2026;33:176.
    PubMed    
    Abstract available
    
    

54. VENTO J, Zhang T, Lotan Y, Woldu S, et al
    Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer.
    Curr Oncol. 2026;33:162.
    PubMed    
    Abstract available
    
    

55. SOUTH N, Mihai IM, Wang V, Agoumi M, et al
    Urachal Signet Ring Cell Carcinoma: A Clinicopathological Analysis of 28 Cases.
    Curr Oncol. 2026;33:153.
    PubMed    
    Abstract available
    
    

56. HAO Z, Yue S, Yao L, Gong Y, et al
    Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder Cancer.
    Biosensors (Basel). 2026;16:171.
    PubMed    
    Abstract available
    
    

57. QIAO Q, Guo R, Sun Z, Shi Y, et al
    Polyphyllin II regulates ROS levels and promotes ferroptosis in bladder cancer cells.
    Mol Med Rep. 2026;33:148.
    PubMed    
    Abstract available
    
    

58. ZHANG Y, Cai L, Chen Y, Bai R, et al
    MRI based unsuperviced clustering on MIBC reveals intratumor heterogeneity phenotypes and neoadjuvant chemotherapy efficacy.
    Cancer Imaging. 2026;26:48.
    PubMed    
    Abstract available
    
    

59. LUO J, Cheng Z, Chen L, Li X, et al
    Correlation analysis of HER2 expression with clinicopathological features and prognosis based on data from 444 patients with urothelial carcinoma.
    BMC Urol. 2026;26:86.
    PubMed    
    Abstract available
    
    

60. GUEDES OLIVA P, Jimenez Marrero P, Espino Espino R, Marrero Dominguez R, et al
    Urachal adenocarcinoma: Case report, literature review, and therapeutic algorithm proposal.
    Actas Urol Esp (Engl Ed). 2026;50:501916.
    PubMed    
    Abstract available
    
    

61. ZHANG Y, Yan R, Wang H, Man J, et al
    From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors.
    Expert Rev Anticancer Ther. 2026;26:463-477.
    PubMed    
    Abstract available
    
    

62. BONATTI M, Valletta R, D'Erme L, Dolciami M, et al
    Preoperative staging of cervical cancer: time to shift from cystoscopy to MRI.
    Eur Radiol. 2025 Oct 4. doi: 10.1007/s00330-025-12039.
    PubMed    
    Abstract available
    
    

63. XIONG L, Li J, Jin X, Cao X, et al
    An Artificial Intelligence-Based Method for Risk Stratification of Urothelial Carcinoma from Liquid-Based Urine Cytology Whole-Slide Images.
    Acta Cytol. 2026;70:211-222.
    PubMed    
    Abstract available
    
    

64. XIAO Y, Yang J, Sun M, Li Y, et al
    The tumor-associated fibroblasts regulate urothelial carcinoma progression.
    J Mol Cell Biol. 2026;17:mjaf032.
    PubMed    
    Abstract available
    
    

65. TRIPATHY SR, Ayyanar P, Das DK, Barik SK, et al
    Plasmacytoid subtype of urothelial carcinoma - Report of two rare cases and unusual features.
    Indian J Pathol Microbiol. 2026;69:174-177.
    PubMed    
    Abstract available
    
    

66. OLUMOYIN KD, Aydin AM, Bazargan S, Bunch B, et al
    PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers.
    bioRxiv [Preprint]. 2026 Mar 13:2025.10.15.682695.
    PubMed    
    Abstract available
    
    

67. ANDERSON HG, Bazargan S, Nusbaum DJ, Poch MA, et al
    A virtual cohort framework with applications to adoptive cell therapy in bladder cancer.
    bioRxiv [Preprint]. 2026 Mar 10:2026.03.06.710135.
    PubMed    
    Abstract available
    
    

68. LOURENCO C, Constancio V, Tavares NT, Monteiro-Reis S, et al
    From cell lines to the clinic: identifying a urinary BlCa-EV signature through comparative proteomics of bladder cancer lysates and extracellular vesicles.
    Cell Commun Signal. 2026 Apr 9. doi: 10.1186/s12964-026-02868.
    PubMed    
    Abstract available
    
    

69. ZHAO M, Wang X, Duan X, Wu C, et al
    Ferroptosis as a therapeutic vulnerability in ARID1A-deficient bladder cancer.
    Commun Biol. 2026 Apr 10. doi: 10.1038/s42003-026-09998.
    PubMed    
    Abstract available
    
    

70. TAN YG, Fong KY, Abern MR, Lim BJH, et al
    Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: A systematic review and meta-analysis.
    Urol Oncol. 2026 Apr 8:111091. doi: 10.1016/j.urolonc.2026.111091.
    PubMed    
    Abstract available
    
    

71. ZENG WR, Xu AW, Cheng ZL, Yong JJ, et al
    [Clear cell adenocarcinoma of the urinary tract: a clinicopathological analysis of nine cases].
    Zhonghua Bing Li Xue Za Zhi. 2026;55:326-332.
    PubMed    
    Abstract available
    
    

72. MOUW KW, Shin KY, Parisi J, Zhai B, et al
    Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026;24:102548.
    PubMed    
    Abstract available
    
    

73. KAYTAZ M, Degirmenci ME, Kucukgergin C, Aydin AF, et al
    Expression of lncRNA-ATB and miR-200c in patients with bladder cancer: a pilot study.
    Lab Med. 2026;57:lmag011.
    PubMed    
    Abstract available
    
    

74. DAI Y, Xiao C, Wang L, Zhou W, et al
    Efficacy and safety of antibody-drug conjugate based therapy in locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis of emerging clinical evidence.
    Front Immunol. 2026;17:1728521.
    PubMed    
    Abstract available
    
    

75. LIU S, Liu X, Liu G, Wang Z, et al
    Nuclear hexokinase 2 couples hyperglycemia to MYC-driven glycolytic and stemness programs in bladder cancer.
    Cell Death Dis. 2026 Apr 8. doi: 10.1038/s41419-026-08714.
    PubMed    
    Abstract available
    
    

76. VAROL N, Belder N, Cetin S, Durgut SG, et al
    Repression of Septin9 inhibits the oncogenic phenotype of bladder cancer.
    Urol Oncol. 2026 Apr 7:111097. doi: 10.1016/j.urolonc.2026.111097.
    PubMed    
    Abstract available
    
    

77. SAHOO B, Nayak MK, Ygl K, Aribaskar S, et al
    Bleeding ileal conduit varices in a postoperative patient of urinary bladder carcinoma: percutaneous transhepatic variceal embolization to the rescue.
    BMJ Case Rep. 2026;19:e266103.
    PubMed    
    Abstract available
    
    

78. SUN M, Wang J, Luo J, Lai S, et al
    Assessment of multi-parameter dual-energy CT in predicting muscle invasion in bladder cancer: comparison with VI-RADS.
    Insights Imaging. 2026;17:96.
    PubMed    
    Abstract available
    
    

79. YANG G, Wang Y, Fan Z, Wei G, et al
    Rapid establishment of KRAS-driven bladder cancer initiation and immune escape models using genetically engineered mice and organoid approaches.
    Front Immunol. 2026;17:1726443.
    PubMed    
    Abstract available
    
    

80. DENG Z, Li Y, Shen Y, Zhou M, et al
    Comprehensive Analysis Based on the Cancer-Immunity Cycle Identifies a Novel Immunosuppressive Subtype of Bladder Cancer.
    Int J Genomics. 2026;2026:9720283.
    PubMed    
    Abstract available
    
    

81. LI W, Xiang C, Xie G, Zhang Y, et al
    Postoperative Neutrophil-to-Albumin Ratio as a Prognostic Marker for Patients with Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Observational Cohort Study.
    Int J Gen Med. 2026;19:595401.
    PubMed    
    Abstract available
    
    

82. GUO B, Xu C, Fu S, Cheng Q, et al
    NQO1-Mediated Anoikis Resistance and Immune Evasion Define a High-Risk Multi-Omic Subtype for Precision Management of T1 High-Grade Bladder Cancer.
    Adv Sci (Weinh). 2026 Apr 7:e23605. doi: 10.1002/advs.202523605.
    PubMed    
    Abstract available
    
    

83. OHNO T, Nakajima Y, Yoshikawa Y, Tsujino T, et al
    Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic Pathways.
    Oncology. 2026 Apr 7:1-18. doi: 10.1159/000551754.
    PubMed    
    Abstract available
    
    

84. LIU Y, Shi ZD, Wei YF, Jiang SY, et al
    Apigenin Suppresses Bladder Cancer via the SIRT6-NCOA2-PPARalpha Axis.
    Int J Biol Sci. 2026;22:3070-3086.
    PubMed    
    Abstract available
    
    

85. ZHENG K, Cui X, Liu Y, Du M, et al
    Risk Factors and Predictive Model for Peripherally Inserted Central Catheter Tip Migration in Patients With Bladder Cancer.
    Arch Esp Urol. 2026;79:352-361.
    PubMed    
    Abstract available
    
    

86. KAYAR K, Verim L, Sonmez D, Kadihasanoglu M, et al
    Distribution of PD-1.5 Gene Variant (rs2227981): A Possible Approach for Risk Assessment in Bladder Cancer.
    Arch Esp Urol. 2026;79:233-240.
    PubMed    
    Abstract available
    
    

87. CHERNOBILSKY V, Gonzalez IT, Favre G
    Efficacy and Safety of Keyhole Limpet Hemocyanin in Bacillus Calmette-Guerin Unresponsive Non-muscle Invasive Bladder Cancer.
    Arch Esp Urol. 2026;79:219-223.
    PubMed    
    Abstract available
    
    

88. VALENCIA NIETO P, Lopez-Campos F, Diezhandino Garcia P, Duque-Santana V, et al
    Adjuvant Radiotherapy After Cystectomy in Muscle-Invasive Bladder Cancer: Indications, Benefits and Remaining Challenges.
    Arch Esp Urol. 2026;79:160-168.
    PubMed    
    Abstract available
    
    

89. CHENG Y, Chen T, Zheng G, Song Z, et al
    PSMD11 stabilizes PGM3 by antagonizing Parkin to promote bladder cancer progression through energy metabolism reprogramming.
    Cell Death Dis. 2026 Apr 6. doi: 10.1038/s41419-026-08691.
    PubMed    
    Abstract available
    
    

90. LEITE TFO, Parreira D, Nunes TF
    Superselective vesical artery embolisation in the management of haemorrhagic radiation cystitis.
    BMJ Case Rep. 2026;19:e270850.
    PubMed    
    Abstract available
    
    

91. ANJUM A, Siddiqui MJ, Ali AMN, Ahmed J, et al
    Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis.
    Ann Med Surg (Lond). 2026;88:2661-2668.
    PubMed    
    Abstract available
    
    

92. SANO T, Taoka R, Miki J, Saito R, et al
    Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer.
    Sci Rep. 2026 Apr 5. doi: 10.1038/s41598-026-46649.
    PubMed    
    
    
    

93. ZENG S, Xing S, Yu X, Liu X, et al
    In-Situ Self-Assembling Multifunctional Peptide-Hydrogel Enables Efficient Bladder Cancer Therapy via Sustained Release of Bacillus Calmette-Guerin and Enhanced Immune Response.
    ACS Appl Mater Interfaces. 2026 Apr 5. doi: 10.1021/acsami.6c01301.
    PubMed    
    Abstract available
    
    

94. HUANG H, Guo L, Sun H, Liu Y, et al
    Saikosaponin D inhibits bladder cancer growth and enhances the synergistic antitumor effect of gemcitabine by targeting PI3K/AKT-mediated ferroptosis.
    Biochem Biophys Res Commun. 2026;816:153709.
    PubMed    
    Abstract available
    
    

95. SUN Z, Wang Y, You S, Ji Q, et al
    CREB1-ROC1 axis drives bladder cancer progression under hypoxic conditions.
    Mol Cell Biochem. 2026 Apr 4. doi: 10.1007/s11010-026-05509.
    PubMed    
    
    
    

96. FAN Z, Li D, Chen W, Li Y, et al
    Application of transformer-enhanced convolutional neural network: multicenter MRI assessment of muscle invasion in bladder cancer.
    Eur Radiol. 2026 Apr 4. doi: 10.1007/s00330-026-12497.
    PubMed    
    Abstract available
    
    

97. MUSHTAQ A, Zabor EC, Adcock B, Dhakal A, et al
    Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study.
    Clin Genitourin Cancer. 2026 Mar 16:102541. doi: 10.1016/j.clgc.2026.102541.
    PubMed    
    Abstract available
    
    

98. BANDO Y, Teishima J, Tobe T, Ueki H, et al
    Adequate Bacillus Calmette-Guerin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival study.
    Urol Oncol. 2026 Apr 2:111087. doi: 10.1016/j.urolonc.2026.111087.
    PubMed    
    Abstract available
    
    

99. ZAURITO P, Scilipoti P, Longoni M, de Angelis M, et al
    Risk stratification of Ta high-grade non-muscle-invasive bladder cancer: Insights from a multicenter cohort study.
    Urol Oncol. 2026 Apr 2:111089. doi: 10.1016/j.urolonc.2026.111089.
    PubMed    
    Abstract available
    
    

100. ALRAMADNEH TN, Mutee AF, Kubaev A, Qayumova S, et al
     Circulating biomarkers in bladder cancer: emerging evidence and future directions for personalized therapy.
     Clin Chim Acta. 2026;588:120992.
     PubMed    
     Abstract available
     
     

101. XU H, Wu J, Qin J, Li Z, et al
     Dual-Interface Hierarchical Assembly of Asymmetric ICG-Lipid Conjugates Enables Finite J-type Aggregation and Two-Stage NIR-II Fluorescence Enhancement.
     Nano Lett. 2026;26:4296-4305.
     PubMed    
     Abstract available
     
     

102. SHIGEHISA R, Fukata S, Pustimbara A, Yoshimura R, et al
     Cytology-stratified evaluation of carcinoma in situ detection using 5-aminolevulinic acid-based photodynamic diagnosis.
     Photodiagnosis Photodyn Ther. 2026;58:105431.
     PubMed    
     Abstract available
     
     

103. MULLER DC, Murtha AJ, Bacon JVW, Stephenson M, et al
     Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.
     Nat Commun. 2026;17:3263.
     PubMed    
     Abstract available
     
     

104. DEY P, Muralidaran C
     Comparative Evaluation of Transfer Learning Models for Detecting Malignant Cells in Urinary Cytology.
     Cytopathology. 2026;37:232-239.
     PubMed    
     Abstract available
     
     

105. HIRAO K, Sano T, Taniguchi H, Yanishi M, et al
     Risk factors and management of hypotension and nausea during 5-aminolevulinic acid-assisted transurethral resection of bladder tumors under spinal anesthesia.
     Photodiagnosis Photodyn Ther. 2026;58:105365.
     PubMed    
     Abstract available
     
     

106. JHA S, Lobo A, Sangoi AR, Kandukuri SR, et al
     Molecular characterization of clear cell adenocarcinoma of the urinary bladder.
     Histopathology. 2026;88:1167-1183.
     PubMed    
     Abstract available
     
     

107. CHILD F, Lunj S, Gough J, Humphries MJ, et al
     The hypoxic ECM and neutrophils in MIBC immunotherapy resistance.
     Nat Rev Urol. 2026;23:236-255.
     PubMed    
     Abstract available
     
     

108. YANG M, Yao Y, Wang K, Qi L, et al
     Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China.
     Virchows Arch. 2026;488:819-830.
     PubMed    
     Abstract available
     
     

109. DENG H, Mi Y, Zhang L, Tan Y, et al
     ARIH2 Ubiquitination Regulates NUPR1 to Inhibit Ferroptosis in Bladder Cancer.
     J Cell Mol Med. 2026;30:e71147.
     PubMed    
     Abstract available
     
     

110. HUI K, Gao Y, Huang J, Xu S, et al
     Correction: RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.
     Cell Death Dis. 2026;17:393.
     PubMed    
     
     
     

111. HAO Y, Niu L, Shih YA, Gao P, et al
     A nurse-led cross-sectional latent profile analysis of fear of cancer recurrence in patients with non-muscle-invasive bladder cancer.
     Medicine (Baltimore). 2026;105:e48370.
     PubMed    
     Abstract available
     
     

112. BJORNSSON O, Geirsson G, Leifsson AS, Nikulasson SThorn, et al
     Early recurrence after primary TURBT for non-muscle-invasive bladder cancer in Iceland: the critical role of surgical quality.
     Scand J Urol. 2026;61:131-137.
     PubMed    
     Abstract available
     
     

113. MESINOVIC D, Bobjer J, Hagberg O, Aljabery F, et al
     Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer.
     Scand J Urol. 2026;61:127-130.
     PubMed    
     Abstract available
     
     

114. MAI M, Tran V, Zhu A, Appiah D, et al
     Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients.
     Bladder Cancer. 2026;12:23523735261438727.
     PubMed    
     Abstract available
     
     

115. ZHU YP, Bian XJ, Ye DW, Yao XD, et al
     [Expression of Concern] Pseudomonas aeruginosa-mannose-sensitive hema-gglutinin inhibits proliferation and induces apoptosis in a caspase-dependent manner in human bladder cancer cell lines.
     Oncol Lett. 2026;31:208.
     PubMed    
     
     
     

116. LIU Y, Chen Y, Ye S, Hu J, et al
     Microwave-Responsive MnFe-Based Molybdenum Disulfide Nanoflowers for Enhanced Thermal-Dynamic-Chemo Synergistic Therapy in Bladder Cancer.
     Int J Nanomedicine. 2026;21:587614.
     PubMed    
     Abstract available
     
     

117. PACINI P, Orecchia L, Asimakopoulos AD, Manfredi M, et al
     The role of Bladder EpiCheck((R)) test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study.
     Urologia. 2026 Apr 16:3915603261440213. doi: 10.1177/03915603261440213.
     PubMed    
     Abstract available
     
     

118. WANG Y, Gong S, Shen J, Liu G, et al
     Integrative analysis of myeloid cell signatures identifies a prognostic risk model and potential mechanisms in bladder cancer.
     Biol Direct. 2026 Apr 16. doi: 10.1186/s13062-026-00785.
     PubMed    
     
     
     

119. GIATSOGLOU M, Chatzistavrou D, Sopczynski JM, Feng G, et al
     Clinical Outcomes in Bacillus Calmette-Guerin-Exposed Non-Muscle-Invasive Bladder Cancer.
     JAMA Netw Open. 2026;9:e267470.
     PubMed    
     Abstract available
     
     

120. SYCHEVA IN, Oleynikova NA
     [The features of cancer-associated fibroblasts as components of tumor stroma in bladder cancer].
     Arkh Patol. 2026;88:87-93.
     PubMed    
     Abstract available
     
     

121. WANG L, Zhang J, Liu Y, Sun Y, et al
     Machine learning prediction of postoperative recurrence in bladder cancer using clinical and laboratory indicators.
     Sci Rep. 2026 Apr 15. doi: 10.1038/s41598-026-48493.
     PubMed    
     
     
     

122. WANG J, Liu H, Li K, Xie Z, et al
     Therapeutic potential of asparagus polysaccharide in bladder cancer treatment via modulation of PI3K/AKT/mTOR signaling.
     Sci Rep. 2026 Apr 15. doi: 10.1038/s41598-026-47595.
     PubMed    
     Abstract available
     
     

123. UYSAL D, Reible B, Wildner L, Steidler A, et al
     Concordance and prognostic value of antibody drug conjugate and checkpoint inhibition targets in matched bladder cancer specimens from transurethral resection of the bladder, radical cystectomy and lymphadenectomy.
     Urol Oncol. 2026 Apr 14:111095. doi: 10.1016/j.urolonc.2026.111095.
     PubMed    
     Abstract available
     
     

124. LIANG S, Qie YK, Jia KP, Bai YD, et al
     [Efficacy and safety of transvaginal assisted total intracavitary orthotopic neobladder surgery for female urothelial carcinoma of the bladder].
     Zhonghua Yi Xue Za Zhi. 2026;106:1484-1488.
     PubMed    
     Abstract available
     
     

125. ZHU L, Liu Y, Lan J, Cai E, et al
     Identification of MYC co-expression gene: POLR3G is associated with cell senescence, immunotherapy, chemotherapy responses, and clinical prognosis in bladder cancer patients.
     Transl Oncol. 2026;68:102770.
     PubMed    
     Abstract available
     
     

126. ZHAO C, Hou D, Wang K, Chen J, et al
     Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer.
     Sci Adv. 2026;12:eaeb9764.
     PubMed    
     Abstract available
     
     

127. PARK C, Hwangbo H, Hong SH, Jeong HJ, et al
     5-Aminoimidazole-4-carboxamide riboside, an AMPK activator, enhances TRAIL-mediated apoptosis in human bladder cancer cells in a p38 MAPK-dependent manner.
     Genes Genomics. 2026 Apr 15. doi: 10.1007/s13258-026-01764.
     PubMed    
     
     
     

128. KANESVARAN R, Giannatempo P, Filicevas A
     Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer-A Podcast.
     Adv Ther. 2026 Apr 15. doi: 10.1007/s12325-026-03535.
     PubMed    
     Abstract available
     
     

129. ZHANG M, Zhou Y
     Bidirectional Longitudinal Associations Among Health-Related Quality of Life, Emotional Expressivity, and Readiness to Return to Work in Patients with Non-Muscle-Invasive Bladder Cancer Receiving Intravesical Therapy: A Three-Wave Cohort Study.
     Patient Prefer Adherence. 2026;20:594081.
     PubMed    
     Abstract available
     
     

130. BAJDAK-RUSINEK K, Jankowska K, Sundararajan V, Sieron L, et al
     ESRP2 constrains EMT plasticity associated with ZEB1 expression in bladder cancer.
     Front Oncol. 2026;16:1764850.
     PubMed    
     Abstract available
     
     

131. PUSTAKE M, Railkar A, Ganiyani MA, Khosla AA, et al
     Trends in preferred place of death among patients with bladder cancer in the United States, 2000 to 2020.
     Palliat Support Care. 2026;24:e108.
     PubMed    
     Abstract available
     
     

132. ANDRZEJCZAK A, Krajewski W, Jaskula E, Chorbinska J, et al
     Soluble immune checkpoints as diagnostic biomarkers in bladder cancer.
     Biomark Res. 2026;14:44.
     PubMed    
     Abstract available
     
     

133. PENG S, Liu Y, Huang P, Liu Q, et al
     MTHFD1L in muscle invasive bladder cancer: a multi-cohort study on prognosis and therapeutic response.
     World J Surg Oncol. 2026 Apr 14. doi: 10.1186/s12957-026-04346.
     PubMed    
     Abstract available
     
     

134. ZHA J, Guo X, Liao W, Wu P, et al
     Inhibition of TRPC6 channel suppresses bladder cancer proliferation by disrupting store-operated calcium entry.
     Sci Rep. 2026 Apr 14. doi: 10.1038/s41598-026-45219.
     PubMed    
     
     
     

135. MUSAEV A, Akpinar C, Ulgen TK, Erkmen S, et al
     Impact of Different Surveillance Intervals on Recurrence and Progression in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer.
     Clin Genitourin Cancer. 2026;24:102543.
     PubMed    
     Abstract available
     
     

136. SUN X, Qi Q, Ding X, Wang X, et al
     The Tumor-Promoting Role of ADM in Bladder Cancer and its Mediated Mechanisms of Cell Death via PKR and STAT1.
     Appl Biochem Biotechnol. 2026 Apr 14. doi: 10.1007/s12010-026-05691.
     PubMed    
     
     
     

137. CHA JH, Kim KJ, Yun SG, Nam MH, et al
     Diagnostic Aspects of a Bacillus Calmette-Guerin (BCG) Infection Following Intravesical Treatment for Bladder Cancer.
     Clin Lab. 2026;72.
     PubMed    
     Abstract available
     
     

138. 
     Downregulation of Long Noncoding RNA TUG1 Inhibits Proliferation and Induces Apoptosis Through the TUG1/miR-142/ZEB2 Axis in Bladder Cancer Cells [Retraction].
     Onco Targets Ther. 2026;19:614701.
     PubMed    
     Abstract available
     
     

139. LIPKA U, Orywal K, Gudowska-Sawczuk M
     Matrix Metalloproteinases and Pro-Inflammatory Cytokines in Bladder Cancer: Diagnostic and Prognostic Perspectives: Narrative Review.
     Int J Mol Sci. 2026;27:3218.
     PubMed    
     Abstract available
     
     

140. CANCERS EDITORIAL OFFICE
     Expression of Concern: Juengel et al. Mechanisms Behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. Cancers 2019, 11, 777.
     Cancers (Basel). 2026;18:1077.
     PubMed    
     Abstract available
     
     

141. ESTEBAN-VILLARRUBIA J, de Velasco G
     Targeting metastatic bladder cancer when money is an issue.
     Nat Rev Urol. 2026 Apr 13. doi: 10.1038/s41585-026-01142.
     PubMed    
     
     
     

142. NIU S, Yang P, Yao Y, Tang X, et al
     NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer.
     Cell Death Discov. 2026 Apr 14. doi: 10.1038/s41420-026-03091.
     PubMed    
     Abstract available
     
     

143. FAN X, Li Z, Gao Q, Huang P, et al
     TRIM28 orchestrates SUMO-ubiquitin crosstalk to stabilize PPARG and drive bladder cancer progression.
     Cell Death Dis. 2026 Apr 13. doi: 10.1038/s41419-026-08745.
     PubMed    
     Abstract available
     
     

144. TONG H, Li T, Zhu J, Dou Q, et al
     RBM11 drives malignant progression of bladder cancer by regulating GNPDA1-PKM2 axis.
     iScience. 2026;29:115402.
     PubMed    
     Abstract available
     
     

145. LIU Q, Zhou P, Tian D
     Identification of RNA processing-related gene-based bladder cancer subtypes for prognosis and immune landscape assessment.
     Transl Androl Urol. 2026;15:74.
     PubMed    
     Abstract available
     
     

146. OSKARSSON E, Johansson M, Liden O, Alamdari F, et al
     Comorbidity alterations between time for diagnosis and radical cystectomy in patients with muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.
     Transl Androl Urol. 2026;15:77.
     PubMed    
     Abstract available
     
     

147. MENG H, Wang X, Liu P, Liu Q, et al
     Development and feasibility assessment of an automated, synthetic CT-guided plan selection system for bladder cancer adaptive radiotherapy: a retrospective pilot study.
     Transl Cancer Res. 2026;15:194.
     PubMed    
     Abstract available
     
     

148. MOLNAR A, Montoya-Cerrillo D, Montgomery EA, Kryvenko ON, et al
     The ancillary role of D2-40 in demonstration of muscularis propria invasion vs desmoplastic reaction in invasive urothelial carcinoma of the bladder.
     Am J Clin Pathol. 2026;165:aqag025.
     PubMed    
     Abstract available
     
     

149. GUPTA S, Kosari F, Thapa P, Murphy SJ, et al
     Sarcomatoid urothelial carcinoma with constitutive PD-L1 overexpression.
     Am J Clin Pathol. 2026;165:aqag023.
     PubMed    
     Abstract available
     
     

150. WEN J, Zhou B, Zhang H, Tang Y, et al
     Unlocking caspase-8 enables Pt(IV) to trigger robust caspase-3/GSDME-mediated pyroptosis via drug co-delivery in chemoresistant bladder cancer.
     J Nanobiotechnology. 2026 Apr 12. doi: 10.1186/s12951-026-04449.
     PubMed    
     Abstract available
     
     

151. LI C, Cheng C, Li S, Wang D, et al
     Integration of Node-RADS and Habitat Radiomics for Predicting Occult Nodal Metastasis in Bladder Cancer.
     Ann Surg Oncol. 2026 Apr 12. doi: 10.1245/s10434-026-19624.
     PubMed    
     Abstract available
     
     

152. SCILIPOTI P, Zaurito P, Longoni M, Occhi A, et al
     The impact of age in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
     Urol Oncol. 2026 Apr 11:111085. doi: 10.1016/j.urolonc.2026.111085.
     PubMed    
     Abstract available
     
     

153. WANG J, Lu M, Qi N, Zhang M, et al
     Integrated machine learning and experimental validation reveal S6K2 as a key target of 6PPD-quinone in bladder cancer.
     Ecotoxicol Environ Saf. 2026;316:120085.
     PubMed    
     Abstract available
     
     

154. ANGULO-LOZANO JC, Calvillo-Ramirez A, Noyola-Perez A, Cojuc-Konigsberg G, et al
     Unequal Access to Novel Systemic Therapies for Bladder Cancer: A Global Analysis of Clinical Trials of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates.
     Curr Urol Rep. 2026;27:21.
     PubMed    
     
     
     

155. HAN Y, Zheng Z, Li X, Fan W, et al
     Letter to the editor: TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells.
     J Transl Med. 2026;24:489.
     PubMed    
     
     
     

156. CHEN Q, Chen T, Gan L, Lu Y, et al
     Mitophagy in bladder cancer: a double-edged sword in tumor progression and therapy.
     J Transl Med. 2026;24:523.
     PubMed    
     Abstract available
     
     

157. YAO K, Wang L, Wang J, Liu J, et al
     FTO-mediated m6A demethylation inhibits bladder cancer progression via decreasing EMG1 and reducing ribosome biosynthesis.
     Biochim Biophys Acta Mol Cell Res. 2026;1873:120147.
     PubMed    
     Abstract available
     
     

158. HAN X, Dong S, Wang Y, Fang X, et al
     Grape seed proanthocyanidin extract suppresses bladder cancer by dual blockade of IMPDH1/2-mediated purine and pyrimidine nucleotide biosynthesis.
     J Ethnopharmacol. 2026 Apr 8:121663. doi: 10.1016/j.jep.2026.121663.
     PubMed    
     Abstract available
     
     

159. SONG Y, Yang Y, Qin J, Zhang Q, et al
     Transformer-Enhanced Joint Information Extraction Framework for Bladder Cancer Medical Dialogue Analysis.
     IEEE J Biomed Health Inform. 2026;PP.
     PubMed    
     Abstract available
     
     

160. MENBARI OSKOUIE I, Khatami F, Mesbah G, Baghdadabad LZ, et al
     Melatonin enhances the antitumor and immunomodulatory effects of Bacillus Calmette-Guerin immunotherapy in a murine bladder cancer model.
     Mol Biol Rep. 2026;53:600.
     PubMed    
     Abstract available
     
     

161. BAO Q, Yoshioka T, Sato S, Goto S, et al
     Correlation-Based Morphometric Analysis Reveals Structural Remodeling of Platelet-Bound Circulating Tumor Cells in Urothelial Carcinoma.
     Anal Chem. 2026;98:10668-10675.
     PubMed    
     Abstract available
     
     

162. ANDERSEN L, Lindskrog SV, Nordentoft I, Frydendahl A, et al
     Cell-Free DNA-Derived Immune Cell Ratios Uncover Cancer-Associated Systemic Changes.
     Cancer Res Commun. 2026;6:811-820.
     PubMed    
     Abstract available
     
     

163. MENEGAT ALRS, Menegat BLRS, Braz LDG, Piccoli MVF, et al
     Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis.
     Immunotherapy. 2026;18:139-155.
     PubMed    
     Abstract available
     
     

164. MAHADEVAN KK, Kalluri R
     Tumor-restraining fibroblasts emerge after chemotherapy specifically in responders.
     Cancer Cell. 2026;44:708-709.
     PubMed    
     Abstract available
     
     

165. LI H, Argani P, Gross JM, Zhu J, et al
     Loss of Methylthioadenosine Phosphorylase (MTAP) Expression: A Potentially Useful Tool for Distinguishing Sarcomatoid Urothelial Carcinoma From Inflammatory Myofibroblastic Tumor.
     Mod Pathol. 2026;39:100980.
     PubMed    
     Abstract available
     
     

166. LI H, Mou Y, Liu Z, Yu C, et al
     Robotic Ureteroileal Bypass Repair for Post-Cystectomy Bricker Ureteroenteric Anastomotic Strictures: Stepwise Approach and Clinic Outcomes.
     Ann Surg Oncol. 2026;33:4850-4857.
     PubMed    
     Abstract available
     
     

167. YANG Y, Wu Y, Yang K, Song G, et al
     Preliminary Experience of Transurethral Thulium Laser En Bloc Resection of Paraganglioma of the Urinary Bladder.
     Ann Surg Oncol. 2026;33:4806-4811.
     PubMed    
     Abstract available
     
     

168. GUTIU AG, Marrah AJ, Voss BB, Cowan BC, et al
     Allow Aloe to Do the Work: Aloe vera Constrains Growth of Bladder Cancer Cells and Modulates Expression of Key Costimulatory Molecules.
     Anticancer Res. 2026;46:1883-1892.
     PubMed    
     Abstract available
     
     

169. SATO T, Sano T, Adachi H, Ikeda Y, et al
     Clinicopathological Characteristics and Clinical Course of Non-muscle-invasive Bladder Cancer Secondary to Radical Nephroureterectomy.
     Anticancer Res. 2026;46:2077-2086.
     PubMed    
     Abstract available
     
     

170. SUGIYAMA Y, Naiki T, Morikawa T, Odagiri K, et al
     Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab.
     Anticancer Res. 2026;46:2187-2198.
     PubMed    
     Abstract available
     
     

171. LIAO CH, Chang WS, Chang SY, Wang YC, et al
     Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic Architecture of Bladder Cancer Risk.
     Anticancer Res. 2026;46:1861-1874.
     PubMed    
     Abstract available
     
     

172. SIVA J, Aydogdu C, Heller N, Jonnalagadda R, et al
     Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
     BJU Int. 2026 Apr 2. doi: 10.1111/bju.70269.
     PubMed    
     Abstract available
     
     

173. HJORT PB, Jensen JB, Ernst A
     Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
     BJU Int. 2026 Mar 28. doi: 10.1111/bju.70267.
     PubMed    
     Abstract available
     
     

174. FU MZ, Packiam VT, Byrne J
     Response to comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
     BJU Int. 2026 Apr 8. doi: 10.1111/bju.70271.
     PubMed    
     
     
     

175. KUMAR V, Kant R
     Comment on 'Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer'.
     BJU Int. 2026 Apr 6. doi: 10.1111/bju.70268.
     PubMed    
     
     
     

176. RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al
     Digital Uromonitor(R) outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the 'External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Manageme
     BJU Int. 2026 Apr 6. doi: 10.1111/bju.70230.
     PubMed    
     Abstract available
     
     

177. XING Z, Xu H, Lin P, Hong Y, et al
     ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.
     Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03364.
     PubMed    
     Abstract available
     
     

178. TEKE K, Ozer C, Yaprak Bayrak B, Reyhancan IA, et al
     Boron neutron capture therapy (BNCT) for experimental bladder cancer: systemic or intravesical approach.
     Br J Cancer. 2026 Apr 17. doi: 10.1038/s41416-026-03418.
     PubMed    
     Abstract available
     
     

179. LEE YHA, Wong CM, Liu AQ, Teoh JY, et al
     The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.
     Curr Opin Urol. 2026;36:244-249.
     PubMed    
     Abstract available
     
     

180. AHMAD A, Lepiarczyk O, Birtle AJ
     Personalised medicine in urothelial carcinoma: where do we stand and what is the way to go?
     Curr Opin Urol. 2026;36:250-256.
     PubMed    
     Abstract available
     
     

181. ALIAGA A, Avila C, Fernandez MI
     Navigating bladder preservation in Bacillus Calmette-Guerin-unresponsive disease: how much risk is too much?
     Curr Opin Urol. 2026;36:235-243.
     PubMed    
     Abstract available
     
     

182. ZHOU Q, Ma H
     Re: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
     Eur Urol. 2026 Apr 8:S0302-2838(26)02047-6. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

183. COLD KM, Vasquez JL
     Re: Jethro C.C. Kwong, Zizo Al-Daqqaq, Yashan Chelliahpillai, et al. Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression R
     Eur Urol. 2026 Apr 7:S0302-2838(26)02064-6. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

184. LI D
     Re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).
     Eur Urol. 2026 Apr 2:S0302-2838(26)02045-2. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

185. ZHOU J, Liu P
     Re: Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
     Eur Urol. 2026 Apr 2:S0302-2838(26)02051-8. doi: 10.1016/j.eururo.2026.
     PubMed    
     
     
     

186. FUJITA N
     Editorial Comments to "Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care".
     Int J Urol. 2026;33:e70452.
     PubMed    
     
     
     

187. USUI A, Hara T, Oka S, Sakaguchi K, et al
     Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer: Real-World Incidence and Concomitant Medication Effects.
     Int J Urol. 2026;33:e70448.
     PubMed    
     Abstract available
     
     

188. HATAKEYAMA S, Yamamoto K, Yamamoto H, Yasui T, et al
     Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
     Int J Urol. 2026;33:e70450.
     PubMed    
     Abstract available
     
     

189. MUTA R, Fukushima H, Tanaka H, Numao N, et al
     Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).
     Int J Urol. 2026;33:e70459.
     PubMed    
     Abstract available
     
     

190. RUSSO P, Foschi N, Lentini N, Bizzarri FP, et al
     Perioperative outcomes following open radical cystectomy in the setting of locally advanced bladder cancer.
     Int Urol Nephrol. 2026 Apr 9. doi: 10.1007/s11255-026-05127.
     PubMed    
     Abstract available
     
     

191. 
     Body Size and Bladder Cancer Risk: A Pooled Analysis of Prospective Studies From the National Cancer Institute Cohort Consortium.
     J Clin Oncol. 2026 Apr 17:JCO2502155. doi: 10.1200/JCO-25-02155.
     PubMed    
     Abstract available
     
     

192. PEDERSEN GL, Mogensen K, Rosthoj S, Erikson MS, et al
     In-Office Laser Coagulation of Ta Bladder Tumor Compared With Transurethral Resection of Bladder Tumor: 12 Months Follow-Up Randomized Clinical Trial.
     J Urol. 2026;215:535-543.
     PubMed    
     Abstract available
     
     

193. XIAO M, Ma Y, Zhang G, Chen G, et al
     SRSF10 promotes cisplatin resistance in bladder cancer via BIN1 Exon 12 retention and ANXA1 activation.
     Oncogene. 2026 Apr 6. doi: 10.1038/s41388-026-03735.
     PubMed    
     Abstract available
     
     

194. WANG X, Chen E, Yang X, Wang Y, et al
     [Expression of Concern] 5?Azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene.
     Oncol Rep. 2026;55:103.
     PubMed    
     Abstract available
     
     

195. YU G, Jia Z, Dou Z
     [Retracted] miR?24?3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD.
     Oncol Rep. 2026;55:108.
     PubMed    
     Abstract available
     
     

196. WANG Q, Lin Q, Li L, Wei W, et al
     The Predictive Value of Urinary Twist1 Methylation and VI-RADS Score for Residual Tumor before Repeat Transurethral Resection of Bladder Tumor in NMIBC Patients.
     Urol Int. 2026;110:114-124.
     PubMed    
     Abstract available
     
     

197. HINOJOSA-GONZALEZ DE, Salgado-Garza G, Low EL, Saffati-Grunhaus G, et al
     Differences in Postoperative Healthcare Utilization After Robotic and Open Radical Cystectomy: A NSQIP Analysis.
     Urology. 2026;210:71-75.
     PubMed    
     Abstract available
     
     

198. TANUMA K, Shiga M, Sano K, Hamada K, et al
     Systemic administration of liposomal trehalose dimycolate induces NK1.1(+) cell mediated antitumor immunity in bladder cancer.
     BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15951.
     PubMed    
     
     
     

199. KIM JH, Maeng S, Choi J, Lee CU, et al
     The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guerin and an anti-PD-1 inhibitor in bladder cancer.
     BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15890.
     PubMed    
     
     
     

200. CHEN J, Li B, Gan Y, Li P, et al
     TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer.
     PLoS One. 2026;21:e0346131.
     PubMed    
     Abstract available
     
     

201. GUO D, Li X, Xu X, Chen X, et al
     The Physicochemical Synergy Effect of Nanosecond Pulsed Electric Fields (nsPEF) and cisplatin on reversing chemoresistance of bladder cancer.
     PLoS One. 2026;21:e0346699.
     PubMed    
     Abstract available
     
     

202. YE F, Han X, Li W, Huang L, et al
     Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer.
     Proc Natl Acad Sci U S A. 2026;123:e2505125123.
     PubMed    
     Abstract available